Treatment of pulmonary mucormycosis with adjunctive nebulized amphotericin B ( MUCONAB trial): Results of an open‐label randomized controlled trial
Mycoses · 2023-08 · 66 (8) · 688-696
DOI: 10.1111/myc.13591 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Mycoses, online erschienen am 24.04.2023. Verfasst von Valliappan Muthu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonary Medicine, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India. Hauptthemen laut MEDLINE: Mucormycosis, COVID-19. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 37 Literaturangaben.
Abstract (Originalsprache)
Background
The role of nebulized amphotericin B (NAB) in managing pulmonary mucormycosis (PM) is unknown.
Methods
In this open‐label trial, we randomized PM subjects to receive either intravenous liposomal amphotericin B (control arm, 3–5 mg/kg/day) alone or along with nebulized amphotericin B deoxycholate (NAB, 10 mg twice a day, every alternate day). The primary outcomes were: (1) overall response (‘success’ [complete or partial response] or ‘failure’ [stable disease, progressive disease, or death]) at 6 weeks; and (2) the proportion of subjects with adverse events (AE). The key secondary outcome was 90‐day mortality. We performed a modified intention‐to‐treat (mITT) analysis where we included only subjects receiving at least a single dose of NAB.
Results
Fifteen and 17 subjects were randomized to the control and NAB arms; two died before the first dose of NAB. Finally, we included 30 subjects (15 in each arm; mean age 49.8 years; 80% men) for the mITT analysis. Diabetes mellitus ( n = 27; 16/27 were COVID‐19‐associated PM) was the most common predisposing factor. The overall treatment success was not significantly different between the control and the NAB arms (71.4% vs. 53.3%; p = .45). Twenty‐nine subjects experienced any AE, but none discontinued treatment. The 90‐day mortality was not significantly different between the control (28.6%) and NAB arm (53.3%; p = .26).
Conclusion
Adjunctive NAB was safe but did not improve overall response at 6 weeks. A different dosing schedule or nebulized liposomal amphotericin B may still need evaluation. More research is needed to explore other treatment options for PM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pulmonary Medicine, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.
- Department of Medical Mycology, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.
- Department of Cardiovascular and thoracic surgery, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.
- Department of Radiodiagnosis, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.
- Doodhadhari Burfani Hospital, Haridwar, India.
ORCID-Profile: Valliappan Muthu, Shivaprakash Mandya Rudramurthy, Mandeep Garg
Zitieren
APA
Muthu, V., Gogineni, R. R., Agarwal, R., Prasad, K. T., Sehgal, I. S., Dhooria, S., Aggarwal, A. N., Rudramurthy, S. M., Singh, H., Garg, M., & Chakrabarti, A. (2023). Treatment of pulmonary mucormycosis with adjunctive nebulized amphotericin B ( MUCONAB trial): Results of an open‐label randomized controlled trial. Mycoses, 66(8), 688-696. https://doi.org/10.1111/myc.13591
Vancouver
Muthu V, Gogineni RR, Agarwal R, Prasad KT, Sehgal IS, Dhooria S, et al. Treatment of pulmonary mucormycosis with adjunctive nebulized amphotericin B ( MUCONAB trial): Results of an open‐label randomized controlled trial. Mycoses. 2023;66(8):688-696. doi:10.1111/myc.13591
BibTeX
@article{Muthu2023,
author = {Muthu, Valliappan and Gogineni, Ratnakara Rao and Agarwal, Ritesh and Prasad, Kuruswamy Thurai and Sehgal, Inderpaul Singh and Dhooria, Sahajal and Aggarwal, Ashutosh N and Rudramurthy, Shivaprakash Mandya and Singh, Harkant and Garg, Mandeep and Chakrabarti, Arunaloke},
title = {Treatment of pulmonary mucormycosis with adjunctive nebulized amphotericin B ( MUCONAB trial): Results of an open‐label randomized controlled trial},
journal = {Mycoses},
year = {2023},
volume = {66},
number = {8},
pages = {688--696},
doi = {10.1111/myc.13591}
}
EUVIMED